• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经口服胆酸挑战试验定量检测的肝功能和门体分流与发生大的食管静脉曲张风险。

Liver function and portal-systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.

机构信息

Southern California Research Center, Coronado, California, USA.

Mayo Clinic, Jacksonville, Florida, USA.

出版信息

Aliment Pharmacol Ther. 2024 Jul;60(2):246-256. doi: 10.1111/apt.18054. Epub 2024 May 22.

DOI:10.1111/apt.18054
PMID:38778481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11348877/
Abstract

BACKGROUND

The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs). A derivative test, HepQuant DuO, generates an equivalent DSI and simplifies testing by requiring only oral administration of the test solution and two blood samples at 20 and 60 min.

AIMS

Since the DSIs measured from DuO and SHUNT are equivalent, we compared the diagnostic performance for large oesophageal varices (LEVs) between the DSIs measured from DuO and SHUNT tests.

METHODS

This study combined the data from two prospectively conducted US studies: HALT-C and SHUNT-V. A total of 455 subjects underwent both the SHUNT test and esophagogastroduodenoscopy (EGD).

RESULTS

DSI scores correlated with the probability of LEVs (p < 0.001) and demonstrated a stepwise increase from healthy lean controls without liver disease to subjects with chronic liver disease and no, small or large varices. Furthermore, a cutoff of DSI ≤ 18.3 from DuO had a sensitivity of 0.98 (missing only one case) and, if applied to the endoscopy (EGD) decision, would have prevented 188 EGDs (41.3%). The AUROC for DSI from DuO did not differ from that of the reference SHUNT test method (0.82 versus 0.81, p = 0.3500).

CONCLUSIONS

DSI from HepQuant DuO links liver function and physiology to the risk of LEVs across a wide spectrum of patient characteristics, disease aetiologies and liver disease severity. DuO is minimally invasive, easy to administer, quantitative and may aid the decision to avoid or perform EGD for LEVs.

摘要

背景

肝定量 HepQuant SHUNT 肝功能和生理学测试生成疾病严重程度指数(DSI),与临床并发症(如大食管静脉曲张(LEVs))的风险相关。衍生测试 HepQuant DuO 通过仅要求口服测试溶液和 20 分钟和 60 分钟时的两份血液样本,生成等效的 DSI 并简化测试。

目的

由于 DuO 和 SHUNT 测量的 DSI 是等效的,我们比较了 DuO 和 SHUNT 测试测量的 DSI 对大食管静脉曲张(LEVs)的诊断性能。

方法

本研究结合了两项前瞻性美国研究(HALT-C 和 SHUNT-V)的数据。共有 455 名受试者接受了 SHUNT 测试和食管胃十二指肠镜检查(EGD)。

结果

DSI 评分与 LEVs 的概率相关(p<0.001),并且从没有肝脏疾病的健康瘦对照者到患有慢性肝脏疾病且没有、小或大静脉曲张的患者,DSI 呈逐步增加。此外,DuO 的 DSI≤18.3 的截断值具有 0.98 的敏感性(仅漏诊一个病例),如果应用于内镜(EGD)决策,将可避免 188 例 EGD(41.3%)。DuO 来自 DSI 的 AUROC 与参考 SHUNT 测试方法没有差异(0.82 对 0.81,p=0.3500)。

结论

HepQuant DuO 的 DSI 将肝功能和生理学与 LEVs 的风险联系起来,跨越了广泛的患者特征、病因和肝脏疾病严重程度。DuO 是微创、易于管理、定量的,可能有助于决定是否避免或进行 LEVs 的 EGD。

相似文献

1
Liver function and portal-systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.经口服胆酸挑战试验定量检测的肝功能和门体分流与发生大的食管静脉曲张风险。
Aliment Pharmacol Ther. 2024 Jul;60(2):246-256. doi: 10.1111/apt.18054. Epub 2024 May 22.
2
Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.血小板计数、脾脏长度以及血小板计数与脾脏长度之比在慢性肝病或门静脉血栓形成患者食管静脉曲张诊断中的应用
Cochrane Database Syst Rev. 2017 Apr 26;4(4):CD008759. doi: 10.1002/14651858.CD008759.pub2.
3
Rencofilstat Treatment Improves Liver Function in MASH With Advanced Fibrosis as Quantified by HepQuant DuO.根据HepQuant DuO检测,伦考非司他治疗可改善伴有晚期纤维化的非酒精性脂肪性肝炎的肝功能。
Liver Int. 2025 Mar;45(3):e70036. doi: 10.1111/liv.70036.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.失代偿期肝硬化患者食管静脉曲张出血的治疗:网状荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 10;4(4):CD013155. doi: 10.1002/14651858.CD013155.pub2.
6
Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.肝硬化失代偿期食管静脉曲张出血患者的二级预防:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Mar 30;3(3):CD013122. doi: 10.1002/14651858.CD013122.pub2.
7
Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis.肝硬化食管静脉曲张患者的静脉曲张出血一级预防:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 6;4(4):CD013121. doi: 10.1002/14651858.CD013121.pub2.
8
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
9
Low-complexity manual nucleic acid amplification tests for pulmonary tuberculosis in children.用于儿童肺结核的低复杂度手动核酸扩增检测
Cochrane Database Syst Rev. 2025 Jun 25;6(6):CD015806. doi: 10.1002/14651858.CD015806.pub2.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

引用本文的文献

1
Alterations in Liver Perfusion in Adults With Fontan Circulation as Assessed by Dual Cholate Clearance.通过双胆酸盐清除率评估Fontan循环成年患者的肝脏灌注改变
J Am Heart Assoc. 2025 Apr;14(7):e039479. doi: 10.1161/JAHA.124.039479. Epub 2025 Mar 21.
2
Cost-effectiveness of an oral cholate challenge test for the management of patients at risk for large esophageal varices.口服胆酸挑战试验用于管理大食管静脉曲张风险患者的成本效益分析。
PLoS One. 2024 Nov 22;19(11):e0313006. doi: 10.1371/journal.pone.0313006. eCollection 2024.
3
Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study.胆盐分流、口服胆盐激发试验与门静脉高压的内镜下病变:SHUNT-V研究
Aliment Pharmacol Ther. 2025 Jan;61(1):75-87. doi: 10.1111/apt.18386. Epub 2024 Nov 10.

本文引用的文献

1
Within-individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test.个体内重复性的双样本口服胆酸激发试验(DuO)和简化的 HepQuant SHUNT 试验。
Clin Transl Sci. 2024 Apr;17(4):e13786. doi: 10.1111/cts.13786.
2
Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test.肝功能和生理学无创测量的进展:HepQuant DuO检测
Basic Clin Pharmacol Toxicol. 2024 Mar;134(3):385-395. doi: 10.1111/bcpt.13980. Epub 2024 Jan 15.
3
Compartmental model describing the physiological basis for the HepQuant SHUNT test.描述HepQuant分流检测生理基础的房室模型。
Transl Res. 2023 Feb;252:53-63. doi: 10.1016/j.trsl.2022.08.002. Epub 2022 Aug 7.
4
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识:门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
5
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.EASL 临床实践指南:非侵入性检测评估肝脏疾病严重程度和预后——2021 更新版。
J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21.
6
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.代偿期慢性肝病患者门静脉高压的非侵入性诊断。
Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.
7
HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease.HepQuant SHUNT 可在临床代偿性慢性肝病的早期阶段检测门静脉高压。
Clin Gastroenterol Hepatol. 2022 Apr;20(4):e890-e894. doi: 10.1016/j.cgh.2021.04.030. Epub 2021 Apr 22.
8
Predicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test.使用 Hepquant-SHUNT 测试预测肝硬化患者的临床失代偿。
Aliment Pharmacol Ther. 2021 Apr;53(8):928-938. doi: 10.1111/apt.16283. Epub 2021 Feb 8.
9
The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology.HepQuant SHUNT 肝功能和生理学检测疾病严重程度指数的个体内可重复性。
Transl Res. 2021 Jul;233:5-15. doi: 10.1016/j.trsl.2020.12.010. Epub 2021 Jan 2.
10
Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中 M 和 XL 探头测量肝脏硬度的统一解读。
Gut. 2019 Nov;68(11):2057-2064. doi: 10.1136/gutjnl-2018-317334. Epub 2019 Jan 18.